Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 Combined With Progestins for Fertility-sparing Treatment in MMRd Endometrial Cancer
NCT06914297Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in endometrial cancer (EC), sponsored by Fudan University. Primary endpoint: Complete Response Rate at 3 months. Started Apr 2025; status: recruiting.
02
Drugs
benmelstobart
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06914297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06914297.